Login
$OVID
$2.44 +$0.04 (1.6%) After hours

$OVID 8-K SEC Filings

Filed On Filing
10 Nov 2026 8-K: Results of Operations and Financial Condition

NEW YORK, November 10, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including...

13 Aug 2026 8-K: Financial Statements and Exhibits

NEW YORK, August 13, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including f...

08 Jul 2026 8-K: Departure/Election of Directors or Officers; Compensation

On July 5, 2026, Ovid Therapeutics Inc. (the “Company”) and Jeffrey Rona, who served as the Company’s Chief Business and Financial Officer, principal financial officer, principal accounting officer and secretary, mutually agreed to Mr. R...

11 Jun 2026 8-K: Submission of Matters to a Vote of Security Holders

Ovid Therapeutics Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on June 10, 2026. As of April 15, 2026, the record date for the Annual Meeting, there were 173,037,131 shares of Company common stock o...

03 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation

On May 29, 2026, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) approved, effective as of June 15, 2026, an increase in the size of the Board and, upon recommendation of the Nominating and Corporate Govern...

12 May 2026 8-K: Financial Statements and Exhibits

NEW YORK, May 12, 2026 – Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to pioneering better, gentler medicines for brain disorders with significant unmet need, today provided business updates including fina...

20 Apr 2026 8-K: Other Events

On April 17, 2026, the Series A Warrants (the “Series A Warrants”) issued by Ovid Therapeutics Inc. (the “Company”) in connection with its October 2025 private placement expired. The aggregate number of common shares underlying the Serie...

18 Mar 2026 8-K: Entry into a Material Definitive Agreement; Results of Operations and Financial Condition +1 more

Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 17, 2026, by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and each of the entities listed ...

18 Dec 2025 8-K: Other Events

Ovid Therapeutics Reports Phase 1 Results for the First-Ever Direct Activator of Potassium-Chloride Cotransporter 2 (KCC2), OV350 Intravenous (IV)

11 Dec 2025 8-K: Submission of Matters to a Vote of Security Holders

Ovid Therapeutics Inc. (the “Company”) held a special meeting of stockholders (the “Special Meeting”) on December 11, 2025. As of October 31, 2025, the record date for the Special Meeting, there were 71,212,353 shares of the Company’s co...

12 Nov 2025 8-K: Results of Operations and Financial Condition; Departure/Election of Directors or Officers; Compensation

Ovid Therapeutics Announces Planned Leadership Succession and Reports Business Updates and Third Quarter 2025 Financial Results

03 Oct 2025 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of October 2, 2025, by and among Ovid Therapeutics Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (e...

16 Sep 2025 8-K: Other Events

On September 11, 2025, Ovid Therapeutics Inc., a Delaware corporation (the “Company”), received a formal notification from The Nasdaq Stock Market LLC (“Nasdaq”) confirming that the Company has regained compliance with Nasdaq Listing Rul...

13 Aug 2025 8-K: Financial Statements and Exhibits

NEW YORK, August 13, 2025 -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financ...

10 Jul 2025 8-K: Submission of Matters to a Vote of Security Holders

Ovid Therapeutics Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”) on July 9, 2025. As of May 19, 2025, the record date for the Annual Meeting, there were 71,109,514 shares of Company common stock outst...

25 Jun 2025 8-K: Other Events

Non-dilutive funding extends Ovid’s operational runway; Immedica assumes certain ganaxolone IP costs

13 May 2025 8-K: Results of Operations and Financial Condition

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business upda...

02 May 2025 8-K: Shareholder Director Nominations

On May 1, 2025, the Board of Directors of Ovid Therapeutics Inc. (the “Company”) established July 9, 2025 as the date of the Company’s 2025 Annual Meeting of Stockholders (the “2025 Annual Meeting”). The time and location of the 2025 Ann...

11 Mar 2025 8-K: Results of Operations and Financial Condition

NEW YORK, March 11, 2025 -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today reported business updates and financi...

05 Mar 2025 8-K: Departure/Election of Directors or Officers; Compensation

On March 1, 2025, the Board of Directors (the “Board”) of Ovid Therapeutics Inc. (the “Company”) increased the size of the Board from five to six directors and appointed Stelios Papadopoulos, Ph.D., as a Class I director of the Company, ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support